查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1243430

免疫·肿瘤学的全球市场

Immuno-Oncology
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 224 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

免疫·肿瘤学的全球市场在2030年前将达到783亿美元

在COVID-19后改变的商务环境中，2022年236亿美元的免疫·肿瘤学的全球市场，2030年前将达到783亿美元的规模，在2022年～2030年预计将以年复合成长率16.2％增长。本报告所分析之市场区隔之一的免疫查核点抑制剂年复合成长率将记录16.1％，到分析期间结束时将达到671亿美元。考虑疫情后的復苏，免疫系调整剂市场领域今后8年的年复合成长率将修正为15.8％。

美国市场估算为72亿美元，中国预测年复合成长率15.4％的速度成长

美国的免疫·肿瘤学市场在2022年估算为72亿美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为15.4％，2030年将达到133亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以14.2％和13.8％的速度成长。在欧洲市场中，德国以年复合成长率11.7％成长。

调查对像企业范例

  • AbbVie, Inc.
  • Aduro BioTech, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche AG
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Prometheus Laboratories, Inc.
  • Sanofi SA

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP12538

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Immuno-Oncology Market to Reach $78.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Immuno-Oncology estimated at US$23.6 Billion in the year 2022, is projected to reach a revised size of US$78.3 Billion by 2030, growing at aCAGR of 16.2% over the period 2022-2030. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is projected to record 16.1% CAGR and reach US$67.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immune System Modulators segment is readjusted to a revised 15.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $7.2 Billion, While China is Forecast to Grow at 15.4% CAGR

The Immuno-Oncology market in the U.S. is estimated at US$7.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.2% and 13.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Select Competitors (Total 102 Featured) -

  • AbbVie, Inc.
  • Aduro BioTech, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche AG
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Prometheus Laboratories, Inc.
  • Sanofi SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Immuno-Oncology - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Immuno-Oncology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Immuno-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World 8-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World 8-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Immune System Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for Immune System Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncolytic Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for Oncolytic Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • CANADA
    • TABLE 16: Canada Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 17: Canada 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • JAPAN
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 18: Japan Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Japan 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • CHINA
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: China 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • EUROPE
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 22: Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: Europe 8-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 24: Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Europe 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • FRANCE
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 26: France Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: France 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • GERMANY
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 28: Germany Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Germany 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • ITALY
    • TABLE 30: Italy Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Italy 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • UNITED KINGDOM
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 32: UK Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: UK 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Rest of Europe 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Immuno-Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Asia-Pacific 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 38: Rest of World Recent Past, Current & Future Analysis for Immuno-Oncology by Treatment Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Rest of World 8-Year Perspective for Immuno-Oncology by Treatment Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Treatment Types for the Years 2023 & 2030

IV. COMPETITION